2025-08-21 - Analysis Report
Okay, here's an analysis of Eli Lilly and Co. (LLY) based on the provided data, presented in English with key figures highlighted and summarized.

## Eli Lilly and Co. (LLY) Stock Analysis

Eli Lilly and Co. is a global pharmaceutical company that discovers, develops, manufactures, and markets pharmaceutical products.

### 1. Performance vs. S&P 500 (VOO)

*   **LLY Cumulative Return:** 49.84%
*   **VOO Cumulative Return:** 37.28%
*   **Absolute Spread:** 109.4
*   **Relative Spread:** 40.3 (on a scale where the historical range of -27.3 to 311.6 is 0 to 100)

**Analysis:** LLY has significantly outperformed the S&P 500. The relative spread of 40.3 suggests that while LLY is performing well, it is positioned towards the lower end of its historical outperformance range against the S&P 500.

**Alpha, Beta Analysis:**

| Year       | CAGR    | MDD    | Alpha  | Beta   | Cap(B) |
|------------|---------|--------|--------|--------|--------|
| 2015-2017  | 0.0%    | 0.0%   | 0.0%   | 1.0    | 75.7   |
| 2016-2018  | 0.0%    | 0.0%   | 0.0%   | 1.0    | 103.7  |
| 2017-2019  | 0.0%    | 0.0%   | 0.0%   | 1.0    | 117.8  |
| 2018-2020  | 0.0%    | 0.0%   | 0.0%   | 1.0    | 151.4  |
| 2019-2021  | 0.0%    | 0.0%   | -1.0%  | 0.7    | 247.6  |
| 2020-2022  | 12.0%   | 64.6%  | 22.0%  | 0.2    | 328.0  |
| 2021-2023  | 50.0%   | 64.6%  | 40.0%  | 0.1    | 522.6  |
| 2022-2024  | 85.0%   | 71.6%  | 55.0%  | -0.0   | 692.1  |
| 2023-2025  | 41.0%   | 76.3%  | -2.0%  | -0.0   | 632.4  |

**Analysis:**

*   **CAGR:** Recent periods (2021-2025) show very strong Compound Annual Growth Rate (CAGR), peaking at 85% for 2022-2024.
*   **MDD:** Maximum Drawdown (MDD) is relatively high, indicating significant price volatility.
*   **Alpha:** Alpha is consistently high in recent periods (2020-2024), indicating outperformance relative to the market. But in 2023-2025, Alpha is negative which means underperformance than the market.
*   **Beta:** Beta has been decreasing, suggesting that LLY's price movements are becoming less correlated with the overall market.
*   **Cap:** Market Cap has grown dramatically, showing strong investor confidence.

### 2. Recent Stock Price Movements

*   **Current Price:** 705.44
*   **Previous Close:** 703.21
*   **Change:** 0.32 (Slightly positive)
*   **5-day Moving Average:** 698.47
*   **20-day Moving Average:** 721.35
*   **60-day Moving Average:** 757.97

**Analysis:** The current price is above the 5-day moving average but below the 20-day and 60-day moving averages. This suggests a potential short-term upward trend but a possible longer-term downward trend or consolidation. The small positive change from the previous close indicates minimal upward momentum on the last day.

### 3. Market Risk Indicators & Expected Return

*   **Market Risk Indicator (MRI):** 0.3316 (Low Risk)
*   **RSI:** 43.30 (Neutral)
*   **PPO:** 0.2461
*   **Hybrid Signal:** "cash\_14%\_Buy 80% of cash (155 shares - Caution - MRI:0.33)"
*   **Delta_Previous_Relative_Divergence:** 1.2 (+): 단기상승 (Short-term increase)
*   **Expected Return:** 233.7% (Over a 2+ year investment horizon relative to the S&P 500)

**Analysis:**

*   The low MRI suggests relatively low market risk.
*   The RSI is neutral, not indicating overbought or oversold conditions.
*   The Hybrid Signal recommends buying 80% of available cash, but with caution, aligning with the MRI.
*   The positive change in relative divergence indicates short-term upward momentum.
*   The high expected return suggests strong long-term growth potential compared to the S&P 500.

### 4. Recent News & Significant Events

*   **[2025-08-21]:** Major business developments, regulatory changes, or market events.
*   **[2025-08-18]:** Analyst discussions of recent performance and outlook.
*   **[2025-08-20]:** Notable stock volatility.
*   **[2025-08-17]:** Market experts highlight both risks and opportunities.

**Analysis:** The recent news indicates that LLY is experiencing significant activity and scrutiny, which could be contributing to its volatility. Investors should monitor these developments closely.

### 5. Recent Earnings Analysis

| Date       | EPS  | Revenue       |
|------------|------|---------------|
| 2025-08-07 | 6.3  | 15.56 B$      |
| 2025-05-01 | 3.07 | 12.73 B$      |
| 2024-10-30 | 1.08 | 11.44 B$      |
| 2024-08-08 | 3.29 | 11.30 B$      |
| 2025-08-07 | 3.29 | 11.30 B$      |

**Analysis:**

*   **Strong EPS:** The most recent EPS of 6.3 is significantly higher than previous quarters, indicating strong profitability.
*   **Revenue Growth:** Revenue has shown consistent growth, peaking at $15.56B in the latest quarter. This suggests strong demand for LLY's products.

### 6. Financial Information

**Revenue and Profitability:**

| Quarter      | Revenue     | Profit Margin |
|--------------|-------------|---------------|
| 2025-06-30   | $15.56B     | 84.27%        |
| 2025-03-31   | $12.73B     | 82.53%        |
| 2024-12-31   | $13.53B     | 82.24%        |
| 2024-09-30   | $11.44B     | 81.02%        |
| 2024-06-30   | $11.30B     | 80.80%        |

**Capital and Profitability:**

| Quarter      | Equity      | ROE       |
|--------------|-------------|-----------|
| 2025-06-30   | $18.27B     | 30.98%    |
| 2025-03-31   | $15.76B     | 17.50%    |
| 2024-12-31   | $14.19B     | 31.07%    |
| 2024-09-30   | $14.24B     | 6.81%     |
| 2024-06-30   | $13.56B     | 21.88%    |

**Analysis:**

*   **Strong Revenue and Profit Margin:** Both revenue and profit margins have increased consistently, indicating efficient operations and strong pricing power.
*   **Solid Equity and ROE:** Equity has grown steadily, and ROE is generally strong, reflecting efficient use of shareholder equity to generate profits.

### 7. Overall Summary

LLY has demonstrated strong recent performance, outperforming the S&P 500.  Recent earnings and financial data show robust revenue growth, high profit margins, and solid profitability metrics. The stock price shows slight recent gains but is below its medium and long-term moving averages. The MRI indicates low market risk, and the hybrid signal suggests a cautious buy.  However, investors should be aware of potential volatility given the recent news events and high MDD. The very high expected return suggests significant long-term potential, but the negative Alpha in 2023-2025 and recent volatility warrants careful monitoring.
